**Dawson James Securities Announces Closing of approximately $14.78M Public Offering for Biocept, Inc.**

**Boca Raton, FL, January 31, 2018**-- Dawson James Securities, Inc. in conjunction with Biocept, Inc. (Nasdaq: BIOC) announced today the closing of a “best efforts” public offering of 32,854,606 shares of common stock and warrants to purchase up to an aggregate of 32,854,606 shares of common stock at a combined offering price of $.045. The warrants have a per share exercise price of $.50, are exercisable immediately and will expire five years from the date of issuance. Biocept received proceeds from the offering of approximately $13.3M and intends to use the proceeds for general corporate purposes, to fund ongoing operations and expansion of its business, and to service its existing indebtedness.

Dawson James Securities, Inc. and Westpark Capital, Inc. acted as placement agents in connection with the offering. Dawson James Securities, Inc., served as sole book runner.

The shares described above were offered by Biocept, Inc. pursuant to a registration statement previously filed with, and subsequently declared effective by the Securities and Exchange Commission (“SEC”). A final prospectus supplement relating to the offering was filed with the SEC and is available, along with the accompanying base prospectus, on the SEC's website at <http://www.sec.gov>, or by contacting Dawson James: 1 N. Federal Hwy; Suite 500, Boca Raton, FL 33432 ATTN: Prospectus Department.

**About Biocept, Inc.**

Biocept, Inc., is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. The Company’s patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in plasma (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient’s disease and therapeutic options. For additional information, please visit [www.biocept.com](http://www.biocept.com)

**About Dawson James Securities, Inc.**

Dawson James Securities specializes in capital raising for small and microcap public and private growth companies primarily in the Life Science/Health Care, Technology and Consumer sectors and is a full service investment banking firm with research, institutional and retail sales, and execution trading and corporate services. Headquartered in Boca Raton, FL, Dawson James is privately held with offices in New York, Maryland and New Jersey. [www.dawsonjames.com](http://www.dawsonjames.com)

**Safe Harbor Statement**

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A Of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes”, “expects”, “anticipates” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Member FINRA/SIPC. For more information, please contact:

**Elise Stern, Managing Director, Head of Capital Markets**

[**estern@dawsonjames.com**](mailto:estern@dawsonjames.com)

**561-208-2926**